Anti-Fibrinogen alpha chain antibody (ab231946)
Key features and details
- Rabbit polyclonal to Fibrinogen alpha chain
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Human
- Isotype: IgG
Overview
-
Product name
Anti-Fibrinogen alpha chain antibody
See all Fibrinogen Alpha Chain primary antibodies -
Description
Rabbit polyclonal to Fibrinogen alpha chain -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Recombinant fragment (His-T7-tag) corresponding to Mouse Fibrinogen alpha chain aa 1-300. N-terminal tags. Expressed in E.coli.
Database link: E9PV24 -
Positive control
- IHC-P: Mouse liver tissue. WB: Mouse liver and kidney lysates; Human serum; Recombinant mouse Fibrinogen alpha chain protein.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 44.12% PBS, 55.77% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab231946 was purified by antigen-specific affinity chromatography followed by Protein A affinity chromatography. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab231946 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
Use a concentration of 5 - 20 µg/ml.
|
|
WB |
Use a concentration of 0.2 - 2 µg/ml. Predicted molecular weight: 87 kDa.
|
Notes |
---|
IHC-P
Use a concentration of 5 - 20 µg/ml. |
WB
Use a concentration of 0.2 - 2 µg/ml. Predicted molecular weight: 87 kDa. |
Target
-
Function
Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. -
Sequence similarities
Contains 1 fibrinogen C-terminal domain. -
Domain
A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure. -
Post-translational
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 2243 Human
- Entrez Gene: 14161 Mouse
- Omim: 134820 Human
- SwissProt: P02671 Human
- SwissProt: E9PV24 Mouse
- Unigene: 351593 Human
-
Alternative names
- Ac1873 antibody
- Fba5e antibody
- FGA antibody
see all
Images
-
Formalin-fixed, paraffin-embedded mouse liver tissue stained for Fibrinogen alpha chain using ab231946 at 20 µg/ml in immunohistochemical analysis. DAB staining.
-
Anti-Fibrinogen alpha chain antibody (ab231946) at 2 µg/ml + Mouse liver lysate
Predicted band size: 87 kDa -
Anti-Fibrinogen alpha chain antibody (ab231946) at 2 µg/ml + Human serum
Predicted band size: 87 kDa -
Anti-Fibrinogen alpha chain antibody (ab231946) at 2 µg/ml + Mouse kidney lysate
Predicted band size: 87 kDa -
Anti-Fibrinogen alpha chain antibody (ab231946) at 2 µg/ml + Recombinant mouse Fibrinogen alpha chain protein
Predicted band size: 87 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab231946 has not yet been referenced specifically in any publications.